Indoco Remedies Ltd's Q4FY25 Quarter Results
- 23 May 2025
Result Summary
- Indoco Remedies Ltd reported a 9.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 5.5%.
- Its expenses for the quarter were down by 1.0% QoQ and up 12.7% YoY.
- The net profit decreased 177.6% QoQ and decreased 14.6% YoY.
- The earnings per share (EPS) of Indoco Remedies Ltd stood at 2.4 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 452.30 | 411.40 | 428.66 | 9.9% | 5.5% |
Total Expenses | 439.05 | 443.35 | 389.73 | -1.0% | 12.7% |
Profit Before Tax | 32.98 | -30.96 | 38.93 | -206.5% | -15.3% |
Tax | 10.95 | -2.56 | 13.12 | -527.7% | -16.5% |
Profit After Tax | 22.03 | -28.40 | 25.81 | -177.6% | -14.6% |
Earnings Per Share | 2.40 | -3.10 | 2.80 | -177.4% | -14.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Indoco Remedies Ltd is a pharmaceutical company involved primarily in the manufacturing and sale of a wide range of pharmaceutical products. The company operates in the healthcare industry, focusing on both domestic and international markets. Indoco Remedies offers a variety of products including formulations and active pharmaceutical ingredients (APIs). Although specific recent developments are not provided in the data, the company is known for its commitment to quality and innovation in the pharmaceutical sector. Without access to the latest information, any recent strategic initiatives or market expansions are not detailed here.
Revenue
In the fourth quarter of fiscal year 2025 (Q4FY25), Indoco Remedies Ltd reported a total income of ₹452.30 crores. This represents a quarter-over-quarter (QoQ) increase of 9.9% from the previous quarter (Q3FY25), where the total income was ₹411.40 crores. Year-over-year (YoY), there was a 5.5% increase compared to the fourth quarter of the previous fiscal year (Q4FY24), which recorded a total income of ₹428.66 crores. The rise in income suggests a growth trajectory in the company's revenue, reflecting potentially strong sales performance or other income-generating activities during this period.
Profitability
The company achieved a profit before tax (PBT) of ₹32.98 crores in Q4FY25, a significant turnaround from a loss of ₹30.96 crores in Q3FY25. This represents a dramatic QoQ change of -206.5%. However, compared to Q4FY24, where the PBT was ₹38.93 crores, there is a YoY decrease of 15.3%. The profit after tax (PAT) for Q4FY25 was ₹22.03 crores, recovering from a loss of ₹28.40 crores in Q3FY25, marking a QoQ improvement of -177.6%. Yet, this is a decrease from the PAT of ₹25.81 crores in Q4FY24, showing a YoY decline of 14.6%. The tax expenses for Q4FY25 were ₹10.95 crores, contrasting with a tax credit of ₹2.56 crores in Q3FY25 and a tax expense of ₹13.12 crores in Q4FY24.
Operating Metrics
The total expenses for Indoco Remedies Ltd in Q4FY25 amounted to ₹439.05 crores, which is slightly lower than the ₹443.35 crores reported in Q3FY25, indicating a QoQ reduction of 1.0%. However, there is a YoY increase of 12.7% from Q4FY24, where the total expenses were ₹389.73 crores. The earnings per share (EPS) for Q4FY25 was ₹2.40, recovering from a negative EPS of ₹-3.10 in Q3FY25, marking a QoQ shift of -177.4%. Compared to Q4FY24, where the EPS was ₹2.80, there is a YoY decrease of 14.3%. These financial metrics highlight the company's efforts in managing its expenses and improving its earnings capacity quarter over quarter, despite some annual declines.